---
schema_version: "secwatch.filing_event.v1"
accession: "0001655759-25-000147"
form_type: "8-K"
ticker: "ARVN"
cik: "0001655759"
company_name: "ARVINAS, INC."
filed_at: "2025-09-17T23:59:59+00:00"
generated_at: "2026-05-17T06:22:26.840438+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arvinas and Pfizer to out-license vepdegestrant; cuts 15% workforce, authorizes $100M buyback

## Summary
- Plans to out-license vepdegestrant commercialization rights to a third party; PDUFA date June 5, 2026.
- Additional workforce reduction of 15%; expects $4.5M severance costs in Q3/Q4 2025.
- Total annual cost savings expected to exceed $100M compared to FY 2024, including prior actions.
- Board authorized up to $100M share repurchase program; funded by working capital, no time limit.
- Reaffirms cash runway into H2 2028; three Phase 1 PROTAC degraders (ARV-102, ARV-393, ARV-806) advancing.

## SEC filing metadata
- accession: 0001655759-25-000147
- form_type: 8-K
- ticker: ARVN
- cik: 0001655759
- company_name: ARVINAS, INC.
- filed_at: 2025-09-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.05, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1655759/000165575925000147/0001655759-25-000147-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1655759/000165575925000147/arvn-20250917.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001655759-25-000147
- JSON: https://secwatch.observer/filing/0001655759-25-000147.json
- Plain text: https://secwatch.observer/filing/0001655759-25-000147.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.